Only one study evaluated therapeutic doses of daltaparin (Shprecher et al., 2005).
(2006) conducted a prospective cohort study to determine the incidence of daltaparin (5000 IU daily) accumulation and bleeding during prophylaxis treatment in 115 elderly patients with renal failure.
There are limited data for the LMWHs tinzaparin and daltaparin. Individual LMWHs may behave differently, therefore conclusions about all LMWHs cannot be assumed because most of the data were studied with the use of enoxaparin.